Reactions Weekly | 2021
Carfilzomib
Abstract
Renal impairment: case report A 70-year-old woman developed renal impairment during treatment with carfilzomib for relapsed/refractory multiple myeloma. The woman was diagnosed with multiple myeloma in 2014. Thus, she was treated with bortezomib, cyclophosphamide, dexamethasone, lenalidomide and dexamethasone that led to complete remission. She had relapse of multiple myeloma in 2017. Hence, carfilzomib [route and dosage not stated] and dexamethasone were initiated that led to complete remission. But, she had increase in the serum creatinine levels and urinary protein test showed albuminuria. Thus, carfilzomib-induced renal impairment was considered [duration of treatment to reaction onset not stated]. The woman’s carfilzomib was held along with dexamethasone resulting in improvement of serum creatinine levels.